Chief Scientific Officer

Dr. Falk received his PhD and post-degree training at the University of Florida (UF). During his time as faculty in the UF Department of Pediatrics, he worked closely within the Powell Gene Therapy Center to develop AAV-based gene therapies for neuromuscular diseases. These activities were supported by funding from the National Institutes of Health, Department of Defense, Muscular Dystrophy Association and Children’s Miracle Network. His research has focused on the development of AAV therapies for over 13 years. In his current role as the Head of Gene Therapy Programs at Lacerta, Darin leads development and preclinical activities focused on AAV gene therapies for Lacerta’s therapeutic pipeline.